ERKNet Leila vs KAK

The European Rare Kidney Disease Reference Network (ERKNet), in collaboration with Leila, presents a practical tool designed to support your daily clinical practice. ERKNet experts have developed clinical practice recommendations for a number of rare kidney disease conditions and complemented them with diagnostic pathways and treatment protocols—all easily accessible in one place. With its user-friendly interface, the app also offers helpful tools such as glossaries, kidney function test calculators, and step-by-step decision pathways to guide your clinical decisions. The ERKNet/Leila App is continuously updated with new guidelines and insights, ensuring you always have the most current information at your fingertips. I ERKNet/Leila is your resource for navigating the complexities of rare kidney disease management. Download now and join us in harmonizing patient care! Note: ERKNet/Leila is not a medical device. The ERKNet/Leila app is intended for doctors and medical staff. To be able to use the app, you must confirm this when you start the app for the first time. The information provided by the app is intended for educational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. All content is created and checked by medical specialists, doctors and an experienced editorial team. Nevertheless, we cannot assume any liability for third-party content, such as the content of scores, epidemiological content, regulatory information, specialist information that is included in the glossaries as a knowledge base, and for the guidelines and their content. ERKNet is funded by the European Union within the framework of the EU4Health Programme 2021-2027. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or HADEA. Neither the European Union nor the granting authority can be held responsible for them.

Quick risk-calculator for contrast-induced nephropathy based on validated clinical model KAK-CIN Score is a clinical decision-support tool designed to help healthcare professionals estimate the probability of Contrast-Induced Nephropathy (CIN) in patients who will receive intravascular contrast medium. The algorithm is based on the peer-reviewed study by Kulkarni et al (Indian Journal of Nephrology, 2023) which derived and validated a simplified risk score system. Key features: Input four key patient variables: Estimated Glomerular Filtration Rate (eGFR) Contrast volume (mL) Route of contrast administration (arterial vs intravenous) Presence or absence of Diabetes Mellitus Instantly calculates a risk-percentage for CIN and provides a risk category (e.g., low, moderate, high) and provides the CIN Score. Published Journal: https://indianjnephrol.org/?view-pdf=1&embedded=true&article=af81b65b1e790875fb17d4a368ca9457Aplh7GbponE%3D Why use KAK-CIN Score? The original study included 1,300 patients (derivation 1,000 + validation 300) with an observed incidence of CIN of 3.8 %. The model showed high sensitivity (90.4 %) and specificity (98.8 %) in the validation cohort. Unlike many prior CIN risk models that were limited to cardiac catheterisation, this score covers both intra-arterial and intravenous contrast exposure. Important disclaimer This app is for educational and decision-support purposes only. It does not replace clinical judgement, institutional protocols or specialist consultation. Use results in conjunction with the full clinical context. The authors are not responsible for any clinical outcomes resulting from use of this tool. Always follow local guidelines. Privacy & Security No patient-identifiable data is stored beyond your device.